These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20210719)

  • 1. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications.
    Giorgi MA; Bolaños R; Gonzalez CD; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):54-7. PubMed ID: 20210719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired QT interval prolongation and HERG: implications for drug discovery and development.
    Finlayson K; Witchel HJ; McCulloch J; Sharkey J
    Eur J Pharmacol; 2004 Oct; 500(1-3):129-42. PubMed ID: 15464027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
    Lawrence CL; Pollard CE; Hammond TG; Valentin JP
    J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The continuing evolution of torsades de pointes liability testing methods: is there an end in sight?
    Lee N; Authier S; Pugsley MK; Curtis MJ
    Toxicol Appl Pharmacol; 2010 Mar; 243(2):146-53. PubMed ID: 20005885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
    Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
    Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
    Friedrichs GS; Patmore L; Bass A
    J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT prolongation and safety in the Indian population.
    Dabhi J; Mehta A
    Curr Drug Saf; 2007 Sep; 2(3):200-3. PubMed ID: 18690968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
    Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
    Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key clinical considerations for demonstrating the utility of preclinical models to predict clinical drug-induced torsades de pointes.
    Sager PT
    Br J Pharmacol; 2008 Aug; 154(7):1544-9. PubMed ID: 18536754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A history of the role of the hERG channel in cardiac risk assessment.
    Rampe D; Brown AM
    J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
    Guo L; Guthrie H
    J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
    Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
    J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modelling and evaluation in drug research and development?
    Holbrook M; Malik M; Shah RR; Valentin JP
    J Pharmacol Toxicol Methods; 2009; 59(1):21-8. PubMed ID: 18834945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.